Show simple item record

dc.contributor.authorBoard, Ruth E
dc.contributor.authorDean, Emma J
dc.contributor.authorMitchell, Claire L
dc.contributor.authorWardley, Andrew M
dc.date.accessioned2009-07-06T16:58:31Z
dc.date.available2009-07-06T16:58:31Z
dc.date.issued2006-04
dc.identifier.citationSecond-line treatment of postmenopausal women with advanced breast carcinoma. 2006, 6 (4):613-24 Expert Rev Anticancer Theren
dc.identifier.issn1744-8328
dc.identifier.pmid16613548
dc.identifier.doi10.1586/14737140.6.4.613
dc.identifier.urihttp://hdl.handle.net/10541/72659
dc.description.abstractBreast cancer is the most prevalent cancer in women and, currently, there is no standard of care for the treatment of metastatic disease. Treatment options are based on a number of tumor- and patient-related factors. This review explores some of these options, including the use of hormonal manipulation in the treatment of hormone-positive disease, current chemotherapy options and the use of targeted therapies, such as trastuzumab.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAntineoplastic Agents
dc.subject.meshAntineoplastic Agents, Hormonal
dc.subject.meshBreast Neoplasms
dc.subject.meshDrug Delivery Systems
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshPostmenopause
dc.titleSecond-line treatment of postmenopausal women with advanced breast carcinoma.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK. ruth.board@christie-tr.nwest.nhs.uken
dc.identifier.journalExpert Review of Anticancer Therapyen
html.description.abstractBreast cancer is the most prevalent cancer in women and, currently, there is no standard of care for the treatment of metastatic disease. Treatment options are based on a number of tumor- and patient-related factors. This review explores some of these options, including the use of hormonal manipulation in the treatment of hormone-positive disease, current chemotherapy options and the use of targeted therapies, such as trastuzumab.


This item appears in the following Collection(s)

Show simple item record